|
The Potential Effect of Metformin Therapy on Neutrophil-Lymphocyte Ratio in Patients with Type II Diabetes Mellitus: A New Horizon
|
|
| Author:
|
MOHANAD ADEL MOHAMMED, NAWAR R. HUSSIEN, MARWA S. AL-NIEMI, HAYDER M. ALKURAISHY
|
| Abstract:
|
Type II diabetes mellitus (T2DM) is a chronic metabolic and endocrine disorder characterized by
hyperglycemia, and insulin resistance (IR). Both of IR and T2DM provoke different immunological reactions
reflected through changes in white cell count (WBC), increased neutrophil with reduction of circulating
lymphocytes. Therefore, neutrophil-lymphocyte ratio (NLR) may be a surrogate biomarker to evaluate the
severity of T2DM. Therefore, objective of the present study was to elucidate the potential effect of metformin
pharmacotherapy on NLR in patients with T2DM. In this case-control study, thirty-six patients with T2DM
ages 42-67 years were recruited compared with eighteen healthy controls. The T2DM and healthy controls
were allocated into three groups; Group I: T2DM patient on metformin therapy 1.5g/day (n=20), Group II:
T2DM patient on metformin therapy 850mg/day (n=16) and Group III: Healthy controls (n=18).
Anthropometric and biochemical variables as well as NLR were evaluated. Results: most of cardiometabolic
indices mainly lipid profile, blood pressure, and CRR were higher in T2DM patients compared with healthy
controls (P<0.05). However, T2DM patients on metformin therapy 1.5g/day showed better cardiometabolic,
glycemic indices and WBC and platelets profiles compared with T2DM patients on metformin therapy
850mg/day. Moreover, NLR was higher in T2DM patients compared with healthy controls (P=0.0001).
However, T2DM patients on metformin therapy 1.5g/day showed lower NLR (2.45±1.02) compared with
T2DM patients on metformin therapy 850mg/day(5.28±1.76), (P=0.006). Even so, NLR was not differed in
T2DM patients on metformin therapy 1.5g/day compared with controls (P=0.06). Conclusion: High NLR in
patients with T2DM is linked with underlying inflammatory disorders and poor glycemic indices. Metformintherapy in patients with T2DM leads to dose-dependent reduction on NLR.
|
| Keyword:
|
Type II diabetes mellitus, neutrophil-lymphocyte ratio, Metformin
|
| EOI:
|
-
|
| DOI:
|
https://doi.org/10.31838/ijpr/2021.13.01.608
|
| Download:
|
Request For Article
|
|
|